112 related articles for article (PubMed ID: 20003640)
1. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications.
Acedo L; Díez-Domingo J; Moraño JA; Villanueva RJ
Epidemiol Infect; 2010 Jun; 138(6):853-60. PubMed ID: 20003640
[TBL] [Abstract][Full Text] [Related]
2. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
3. Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida.
Light M; Bauman J; Mavunda K; Malinoski F; Eggleston M
Pediatr Infect Dis J; 2008 Jun; 27(6):512-8. PubMed ID: 18449062
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
6. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
7. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus laboratory surveillance and hospitalization trends in South Texas.
Fergie J; Purcell K
Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S51-4. PubMed ID: 18090201
[TBL] [Abstract][Full Text] [Related]
9. Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
Noyola DE; Zuviri-González A; Castro-García JA; Ochoa-Zavala JR
J Infect; 2007 Feb; 54(2):180-4. PubMed ID: 16580073
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
Paes B; Cole M; Latchman A; Pinelli J
Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
[TBL] [Abstract][Full Text] [Related]
12. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
13. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
14. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
Robinson JL
Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
[No Abstract] [Full Text] [Related]
15. Respiratory syncytial virus infection among hospitalized young children with acute lower respiratory illnesses in Al Ain, UAE.
Uduman SA; Ijaz MK; Kochiyil J; Mathew T; Hossam MK
J Commun Dis; 1996 Dec; 28(4):245-52. PubMed ID: 9057448
[TBL] [Abstract][Full Text] [Related]
16. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children.
Madhi SA; Kuwanda L; Cutland C; Klugman KP
J Clin Virol; 2006 Jul; 36(3):215-21. PubMed ID: 16678480
[TBL] [Abstract][Full Text] [Related]
17. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
18. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.
Singleton RJ; Bruden D; Bulkow LR
Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S46-50. PubMed ID: 18090200
[TBL] [Abstract][Full Text] [Related]
20. Stochastic modeling of the transmission of respiratory syncytial virus (RSV) in the region of Valencia, Spain.
Arenas AJ; González-Parra G; Moraño JA
Biosystems; 2009 Jun; 96(3):206-12. PubMed ID: 19758545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
